Skip to main content

Journal of Cancer Survivorship

Ausgabe 6/2022

Inhalt (23 Artikel)

Supporting breast cancer survivors via text messages: reach, acceptability, and utility of EMPOWER-SMS

Anna C. Singleton, Rebecca Raeside, Stephanie R. Partridge, Justin Tat-Ko, Stephanie Che Mun Sum, Karice K. Hyun, Molly Hayes, Clara K. Chow, Aravinda Thiagalingam, Katherine Maka, Kerry A. Sherman, Elisabeth Elder, Julie Redfern

Open Access

Predicting physical activity change in cancer survivors: an application of the Health Action Process Approach

Sarah J. Hardcastle, Chloe Maxwell-Smith, Martin S. Hagger

Review

A systematic mixed studies review of fear of cancer recurrence in families and caregivers of adults diagnosed with cancer

Allan ‘Ben’ Smith, Verena Shuwen Wu, Sylvie Lambert, Jani Lamarche, Sophie Lebel, Stuart Leske, Afaf Girgis

Review

Large-scale North American cancer survivorship surveys: 2011–2019 update

Ahrang Jung, Shelley S. Kay, Jennifer L. Robinson, Bonny Bloodgood Sheppard, Deborah K. Mayer

Review

Identifying the unmet supportive care needs of people affected by kidney cancer: a systematic review

Amy O’Dea, Craig Gedye, Belinda Jago, Catherine Paterson

Open Access Review

Strategies to self-manage side-effects of adjuvant endocrine therapy among breast cancer survivors: an umbrella review of empirical evidence and clinical guidelines

Louise H. Hall, Natalie V. King, Christopher D. Graham, Sophie M. C. Green, Alice Barber, Richard D. Neal, Robbie Foy, Jane Clark, Kelly E. Lloyd, Samuel G. Smith

Physiological and psychosocial correlates of cancer-related fatigue

Callum G. Brownstein, Rosemary Twomey, John Temesi, James G. Wrightson, Tristan Martin, Mary E. Medysky, S. Nicole Culos-Reed, Guillaume Y. Millet

The current status of survivorship care provision at the state level: a Wisconsin-based assessment

Alexandria L. Cull Weatherer, John K. Krebsbach, Amye J. Tevaarwerk, Sarah C. Kerch, Noelle K. LoConte

Postoperative quality of life and therapy-related impairments of oral cancer in relation to time–distance since treatment

Philipp Jehn, Simon Spalthoff, Fritjof Lentge, Alexander-Nicolai Zeller, Frank Tavassol, Michael-Tobias Neuhaus, Fabian Matthias Eckstein, Gertrud Krüskemper, Nils-Claudius Gellrich, Philippe Korn

Association between aspects of social support and health-related quality of life domains among African American and White breast cancer survivors

Alejandra Hurtado-de-Mendoza, Felisa Gonzales, Minna Song, Esther J. Holmes, Kristi D. Graves, Reuben Retnam, Sara Gómez-Trillos, Katherine Lopez, Megan C. Edmonds, Vanessa B. Sheppard

Zur Zeit gratis COVID-19

Childhood cancer survivorship care during the COVID-19 pandemic: an international report of practice implications and provider concerns

Selina R. van den Oever, Saskia M. F. Pluijm, Rod Skinner, Adam Glaser, Renée L. Mulder, Saro Armenian, Edit Bardi, Claire Berger, Matthew J. Ehrhardt, Jordan Gilleland Marchak, Gabrielle M. Haeusler, Jaap den Hartogh, Lars Hjorth, Tomas Kepak, Izolda Kriviene, Thorsten Langer, Miho Maeda, Catalina Márquez-Vega, Gisela Michel, Monica Muraca, Mohamed Najib, Paul C. Nathan, Anna Panasiuk, Maya Prasad, Jelena Roganovic, Anne Uyttebroeck, Jeanette F. Winther, Lorna Zadravec Zaletel, Elvira C. van Dalen, Helena J. H. van der Pal, Melissa M. Hudson, Leontien C. M. Kremer

Open Access

Evaluation of an electronic psycho-oncological adaptive screening program (EPAS) with immediate patient feedback: findings from a German cluster intervention study

Peter Esser, Leon Sautier, Susanne Sarkar, Georgia Schilling, Carsten Bokemeyer, Uwe Koch, Matthias Rose, Michael Friedrich, Sandra Nolte, Otto Walter, Anja Mehnert-Theuerkauf

Open Access Review

Is stroke incidence increased in survivors of adult cancers? A systematic review and meta-analysis

Melanie Turner, Peter Murchie, Sarah Derby, Ariel Yuhan Ong, Lauren Walji, David McLernon, Mary-Joan Macleod, Rosalind Adam

The prevalence and risk of symptom and function clusters in colorectal cancer survivors

Arnold L. Potosky, Kristi D. Graves, Li Lin, Wei Pan, Jane M. Fall-Dickson, Jaeil Ahn, Kristin M. Ferguson, Theresa H. M. Keegan, Lisa E. Paddock, Xiao-Cheng Wu, Rosemary Cress, Bryce B. Reeve

Zur Zeit gratis COVID-19

Cancer patients attending treatment during COVID-19: intolerance of uncertainty and psychological distress

Miri Cohen, Dana Yagil, Ariel Aviv, Michal Soffer, Gil Bar-Sela

Determinants of sleep quality in 5835 individuals living with and beyond breast, prostate, and colorectal cancer: a cross-sectional survey

Silje Aronsen, Rana Conway, Phillippa Lally, Anna Roberts, Helen Croker, Rebecca J. Beeken, Abigail Fisher

Correction

Correction to: Preventive service utilization among low‑income cancer survivors

Brenna E. Blackburn, Miguel Marino, Teresa Schmidt, John Heintzman, Brigit Hatch, Jennifer DeVoe, Laura Moreno, Nathalie Huguet

Correction

Correction to: Implementation barriers to integrating exercise as medicine in oncology: an ecological scoping review

Mary A. Kennedy, Sara Bayes, Robert U. Newton, Yvonne Zissiadis, Nigel A. Spry, Dennis R. Taaffe, Nicolas H. Hart, Daniel A. Galvão

Correction

Correction to: Sensory signs and symptoms in women with self-reported breast cancer–related lymphedema: a case–control study

An De Groef, Nele Devoogdt, Ceren Gursen, Niamh Moloney, Victoria Warpy, Jolien Daelemans, Lore Dams, Vincent Haenen, Elien Van der Gucht, An‑Kathleen Heroes, Tessa De Vrieze, Elizabeth Dylke

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.